Treatment Evidence
1 Li et al. 2022 — tDCS of DLPFC for Neuropsychiatric Disorders
Full Citation:: Li Q, Fu Y, Liu C, Meng Z@. Transcranial Direct Current Stimulation of the Dorsolateral Prefrontal Cortex for Treatment of Neuropsychiatric Disorders. Frontiers in Behavioral Neuroscience. 2022;16:893955. DOI:: 10.3389/fnbeh.2022.893955 Key Findings::
- DLPFC is central to attention, decision-making, working memory, and executive function
- Anodal tDCS over left DLPFC improves working memory and attentional control in multiple studies
- Mechanism: modulates neuronal excitability of primary executive control regions
- Provides rationale for tDCS as a cognitive enhancement strategy in conditions of executive dysfunctionNote:: Evidence base is primarily from depression and healthy volunteer studies; direct ME/CFS tDCS trials are limited.
2 Neuromodulation: Transcranial Magnetic Stimulation for ME/CFS
Samii et al. 1996 — Decreased Post-Exercise MEP Facilitation in CFS
Full Citation:: Samii A, Wassermann EM, Ikoma K, Mercuri B, George MS, O’Fallon A, Dale JK, Straus SE, Hallett M@. Decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue syndrome or depression. Neurology. 1996;47(6):1410–1414. DOI:: 10.1212/WNL.47.6.1410 PMID:: 8960719 Study Design:: Controlled diagnostic study using TMS as a neurophysiological probe (not therapy) Sample Size:: CFS patients vs. healthy controls (exact n not available from abstract) Key Findings:: After exercise, healthy controls showed motor evoked potential (MEP) amplitudes at 218% of baseline; CFS patients reached only 126%. This near-absence of post-exercise facilitation demonstrates objectively impaired motor cortex modulation in CFS, independent of effort or motivation. Relevance:: Foundational study establishing that ME/CFS involves measurable motor cortex dysfunction. Provides the neurophysiological rationale for therapeutic rTMS: if the motor cortex is hypoexcitable and fails to modulate normally, exogenous stimulation may restore function. Critically, this is an objective neurological finding, not a subjective symptom report.
Starr et al. 2000 — Motor Cortex Excitability in CFS
Full Citation:: Starr A, Scalise A, Gordon R, Michalewski HJ, Caramia MD@. Motor cortex excitability in chronic fatigue syndrome. Clinical Neurophysiology. 2000;111(11):2025–2031. DOI:: 10.1016/S1388-2457(00)00403-3 PMID:: 11068238 Study Design:: Controlled neurophysiology study Key Findings:: CFS patients had significantly higher resting motor thresholds (reduced cortical excitability) and absent post-exercise MEP facilitation, confirming and extending Samii et al. 1996. The motor cortex in CFS requires stronger stimulation to produce a response and fails to upregulate after physical exertion. Relevance:: Independent replication of motor cortex hypoexcitability in CFS. Together with Samii 1996 and Davey 2003, establishes a consistent neurophysiological phenotype that rTMS could theoretically correct.
[Miwa, Inoue 2023 — Dual-Target rTMS Ameliorates ME Symptoms],
Full Citation:: Miwa K, Inoue Y@. Repetitive transcranial magnetic stimulation ameliorates symptoms in patients with myalgic encephalomyelitis (chronic fatigue syndrome). IBRO Neuroscience Reports. 2023;15:335–341. DOI:: 10.1016/j.ibneur.2023.11.002 PMID:: 38025661 Study Design:: Open-label, single-arm (no sham control), \(n=30\) Population:: ME patients (7 men, 23 women), mean age 39\(\pm\) 12 years, enrolled May 2015–March 2021 Protocol:: Intermittent theta burst stimulation (iTBS): 3-pulse bursts at 50 Hz, repeated at 5 Hz, 600 pulses per site. Dual targets: left DLPFC (MRI-guided) and left M1 (motor hot spot). 10 sessions over 2-week inpatient stay. Intensity: 80% resting motor threshold (range 32–80% after tolerability adjustment). Key Findings::
- Performance status: 67% achieved ≥2-point improvement; median decreased from 7 to 5 ($p\\<0.01$)
- Orthostatic intolerance: 83% (10/12) who could not complete standing test at baseline completed it post-treatment ($p\\<0.01$)
- Disequilibrium: 88% (15/17) resolved; prevalence dropped from 57% to 7% ($p\\<0.01$)
- Pain: 70% (7/10) showed ≥4 tender point reduction; median tender points 2$\to$ 0 ($p\\<0.01$)
- No serious adverse effects; 7 patients required intensity reduction for discomfort/headache/dizzinessRelevance:: Largest ME/CFS-specific rTMS study to date. The dual-target approach (DLPFC + M1) and particularly strong effects on orthostatic intolerance and disequilibrium distinguish this from depression-focused TMS protocols. However, the complete absence of sham control is a critical limitation—TMS produces strong expectancy effects, and the inpatient setting (rest, clinical attention) is itself therapeutic.
Certainty Assessment: TMS for ME/CFS (Aggregate)
- Quality: Low (all open-label, no sham controls, no blinding)
- Sample: \(\sim\) 72 patients total across all ME/CFS therapeutic studies
- Replication: Partial (two related Japanese groups; no independent replication outside Japan)
- Mechanistic support: Moderate (diagnostic TMS studies independently confirm motor cortex hypoexcitability)
- Indirect support: Moderate-to-strong (fibromyalgia sham-controlled meta-analyses show effects survive placebo for pain and quality of life: SMD \(-0.35\) to \(-0.70\) (Toh et al. 2022) (Su et al. 2021))
- Guideline status: Not recommended by NICE for ME/CFS; Level B (probable efficacy) for fibromyalgia (Lefaucheur et al. 2020)
- Overall certainty: 0.30 — mechanistic rationale sound, but no controlled ME/CFS evidence exists
- Clinical recommendation: Investigational only; requires sham-controlled RCT before clinical adoption
3 Lang-Illievich et al. 2023 — PEA for Chronic Pain: Systematic Review and Meta-Analysis
Full Citation:: Lang-Illievich K, Klivinyi C, Lasser C, et al. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients. 2023;15(6):1350. DOI:: 10.3390/nu15061350 PMID:: 36986081 Study Design:: Systematic review and meta-analysis of 13 double-blind RCTs Key Findings::
- Pooled effect favors PEA with mean pain reduction of 1.68 points on 11-point scale
- Pain reductions documented at 6 weeks, 8 weeks, and 24–26 weeks, supporting extended treatment
- Safety profile excellent; minimal side effects across all trials
- Superiority of micronized vs.\ standard PEA on clinical outcomes unclear; enhanced solubility may affect absorptionSignificance:: Provides the strongest meta-analytic evidence for PEA in chronic pain, supporting its use in ME/CFS patients with a pain component.